drugset / Trial / NCT07371767
CS-121 APOC3 Base Editing in Children and Adolescents With Hyperchylomicronemia
Phase 0
Recruiting
15 enrolled
Shanghai Jiao Tong University School of Medicine
CorrectSequence Therapeutics Co., Ltd · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Prospective, Single-center, Open-label, Single-arm Clinical Study to Evaluate the Safety and Efficacy of CS-121, an In Vivo Base Editing Therapy Delivered by Lipid Nanoparticles Targeting APOC3, in Children and Adolescents (4-18 years) With Hyperchylomicronemia
Timeline
- Start
- 2026-01-26
- Primary completion
- 2027-10-31
- Completion
- 2041-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS-121 | CRISPR / gene editing | — | — |